BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Izhakian S, Pertzov B, Rosengarten D, Kramer MR. Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: A case report . World J Clin Cases 2022; 10(18): 6105-6109 [PMID: 35949821 DOI: 10.12998/wjcc.v10.i18.6105]
URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6105.htm
Number Citing Articles
1
Yoshiro Kai, Ryosuke Kataoka, Kentaro Suzuki, Eriko Nakamura, Masato Takano, Shigeo Muro. Successful discontinuation of corticosteroids through remission induction therapy with benralizumab for chronic eosinophilic pneumoniaRespirology Case Reports 2024; 12(1) doi: 10.1002/rcr2.1279
2
Andrea Dionelly Murillo, Ana Isabel Castrillon, Carlos Daniel Serrano, Liliana Fernandez-Trujillo. Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping reviewBMC Pulmonary Medicine 2024; 24(1) doi: 10.1186/s12890-024-02868-3
3
Mizuki Inaba, Yasuo Shimizu, Yusuke Nakamura, Hiroaki Okutomi, Akihiro Takemasa, Seiji Niho. Tezepelumab improved chronic eosinophilic pneumonia in severe asthma patients with liver cirrhosisFrontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1381261
4
Luis Pérez de Llano, David Dacal Rivas, Ian Pavord, Mian Muhammad Salman Aslam, Njira Lugogo. Biologics Use in Eosinophilic Lung Disease: Controversies and ConsensusThe Journal of Allergy and Clinical Immunology: In Practice 2026; 14(3): 583 doi: 10.1016/j.jaip.2026.01.022